Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 2/2009

01-02-2009 | Original Article

Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene

Authors: Jia-jia Ma, Bi-liang Chen, Xiao-yan Xin

Published in: Archives of Gynecology and Obstetrics | Issue 2/2009

Login to get access

Abstract

Aims

To investigate the inhibiting mechanism of multi-drug resistance (MDR) using expression vectors of short hairpin RNA (shRNA) in a MDR human ovarian cancer cell line (A2780/cp70).

Methods

Two shRNA expression vectors were constructed and introduced into A2780/cp70 cells. Expression of MRP2 mRNA was assessed by RT-PCR, and Mrp2 expression was determined by Western blot and immunocytochemistry. Apoptosis and sensitization of the cells to cisplatinum were quantified by flow cytometry and methyl-thiazol-tetrazolium (MTT) assays. Cellular cisplatinum accumulation was assayed by laser scanning confocal microscopy (LSCM).

Results

In A2780/cp70 cells transfected with MRP2-A and MRP2-B shRNA expression vectors, RT-PCR showed that MRP2 mRNA expression was reduced by 41.8% (< 0.05), 30.9% (< 0.01) (transient transfection) and 39.6% (< 0.05), 29.4% (< 0.01) (stable transfection), respectively. Western blot and immunocytochemistry showed that Mrp2 expression was significantly and specifically inhibited. Resistance against cisplatinum was decreased from 173- to 119-fold (< 0.05), 64-fold (< 0.01) (transient transfection) and to 117-fold (< 0.05), 60-fold (< 0.01) (stable transfection). Furthermore, shRNA vectors significantly enhanced the cellular cisplatinum accumulation. The combination of shRNA vectors and cisplatinum significantly induced the apoptosis of cells.

Conclusions

shRNA expression vectors effectively reduce MRP2 expression and can restore the sensitivity of drug-resistant cancer cells to conventional chemotherapeutic agents.
Literature
1.
go back to reference Pardridge WM (2004) Intravenous, non viral RN gene therapy of brain cancer [J]. Expert Opin Biol Ther 4(7):1103–1113PubMedCrossRef Pardridge WM (2004) Intravenous, non viral RN gene therapy of brain cancer [J]. Expert Opin Biol Ther 4(7):1103–1113PubMedCrossRef
2.
go back to reference Kartner N, Shales M, Riordan JR, Ling V (1983) Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 43:4413–4419PubMed Kartner N, Shales M, Riordan JR, Ling V (1983) Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 43:4413–4419PubMed
3.
go back to reference Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654PubMedCrossRef Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654PubMedCrossRef
4.
go back to reference Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302PubMedCrossRef Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302PubMedCrossRef
5.
go back to reference Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124–4129PubMed Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124–4129PubMed
6.
go back to reference Ozols RF (1985) Pharmacologic reversal of drug resistance in ovarian cancer. Semin Oncol 12:7–11PubMed Ozols RF (1985) Pharmacologic reversal of drug resistance in ovarian cancer. Semin Oncol 12:7–11PubMed
7.
go back to reference Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA et al (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537–3547PubMed Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA et al (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537–3547PubMed
8.
go back to reference Liedert B, Materna V, Schadendorf D, Thomale J, Lage H (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121:172–176PubMedCrossRef Liedert B, Materna V, Schadendorf D, Thomale J, Lage H (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121:172–176PubMedCrossRef
9.
go back to reference Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–937PubMed Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–937PubMed
10.
go back to reference Milhavet O, Gary DS, Mattson MP (2003) RNA interference in biology and medicine[J]. Pharmacol Rev 55(4):629–648PubMedCrossRef Milhavet O, Gary DS, Mattson MP (2003) RNA interference in biology and medicine[J]. Pharmacol Rev 55(4):629–648PubMedCrossRef
11.
go back to reference Scherr M, Battmer K, Schuhheis B et al (2005) Stable RNA interference (RNAi) and an option for anti-bcrabl therapy[J]. Gene Ther 12(1):l2–2 lCrossRef Scherr M, Battmer K, Schuhheis B et al (2005) Stable RNA interference (RNAi) and an option for anti-bcrabl therapy[J]. Gene Ther 12(1):l2–2 lCrossRef
12.
go back to reference Wohlbold L, van der Kuip H, Miething C et al (2003) Inhibition of berabl gene expression by small interfering RNA sensitizes for imatinib mesylate (ST1571) [J]. Blood 102(6):2236–2239PubMedCrossRef Wohlbold L, van der Kuip H, Miething C et al (2003) Inhibition of berabl gene expression by small interfering RNA sensitizes for imatinib mesylate (ST1571) [J]. Blood 102(6):2236–2239PubMedCrossRef
14.
go back to reference DaRoeha WD, Otsu K, Teixeira SM et al (2004) Tests of cytoplasmic RNA interferece (RNAi) and construction of a tetracyclineinducible T7 promoter system in Trypanosome cruzi [J]. Mol Biochem Parasitol 133(2):175–186CrossRef DaRoeha WD, Otsu K, Teixeira SM et al (2004) Tests of cytoplasmic RNA interferece (RNAi) and construction of a tetracyclineinducible T7 promoter system in Trypanosome cruzi [J]. Mol Biochem Parasitol 133(2):175–186CrossRef
15.
go back to reference Sui GCH, Soohoo C, Afar EB et al (2002) A DNA vector-based RNAi technology to suppres gene expresion in mammalian cells [J]. PNAS 99:5515–5520PubMedCrossRef Sui GCH, Soohoo C, Afar EB et al (2002) A DNA vector-based RNAi technology to suppres gene expresion in mammalian cells [J]. PNAS 99:5515–5520PubMedCrossRef
16.
go back to reference Borkhardt A (2002) Blocking oncogenes in malignant cells by RNA interference—new hope for a highly specific cancer treatment [J]. Cancer Cell 2(2):167–168PubMedCrossRef Borkhardt A (2002) Blocking oncogenes in malignant cells by RNA interference—new hope for a highly specific cancer treatment [J]. Cancer Cell 2(2):167–168PubMedCrossRef
17.
go back to reference Bentires-Alj M, Barbu V, Fillet M et al (2003) NF-KB transcription factor induces drug resistance through MRP2 expression in cancer cells [J]. Oncogene 22:90–97PubMedCrossRef Bentires-Alj M, Barbu V, Fillet M et al (2003) NF-KB transcription factor induces drug resistance through MRP2 expression in cancer cells [J]. Oncogene 22:90–97PubMedCrossRef
18.
go back to reference Hang L, Yang N, Mohamed Hadley A et al (2003) Vector-based RNAi:a novel tool for isoform-specific knock-down of VEGF and anti angiogenesis gene therapy of cancer [J]. Biochem Biophys Res Commun 303(4):1169–1178CrossRef Hang L, Yang N, Mohamed Hadley A et al (2003) Vector-based RNAi:a novel tool for isoform-specific knock-down of VEGF and anti angiogenesis gene therapy of cancer [J]. Biochem Biophys Res Commun 303(4):1169–1178CrossRef
19.
go back to reference Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference [J]. Cancer Cell 2(3):243–247PubMedCrossRef Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference [J]. Cancer Cell 2(3):243–247PubMedCrossRef
20.
go back to reference Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G et al (1999) Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10:1159–1169PubMed Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G et al (1999) Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10:1159–1169PubMed
21.
go back to reference Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D (2001) Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94:492–499PubMedCrossRef Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D (2001) Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94:492–499PubMedCrossRef
22.
go back to reference Sandusky GE, Mintze KS, Pratt SE, Dantzig AH (2002) Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41:65–74PubMedCrossRef Sandusky GE, Mintze KS, Pratt SE, Dantzig AH (2002) Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41:65–74PubMedCrossRef
23.
go back to reference Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S et al (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistanceassociated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5:2798–2805PubMed Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S et al (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistanceassociated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5:2798–2805PubMed
24.
go back to reference Materna V, Pleger J, Hoffmann U, Lage H (2004) RNA expression of MDR1/Pglycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94:152–160PubMedCrossRef Materna V, Pleger J, Hoffmann U, Lage H (2004) RNA expression of MDR1/Pglycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94:152–160PubMedCrossRef
25.
go back to reference Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH et al (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9:767–773PubMed Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH et al (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9:767–773PubMed
26.
go back to reference Hu Xiaoqu, Su Fengxi, Qin Li, Jia Weijuan et al (2006) Stable RNA interference of ErbB–2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo [J]. Biochem Biophys Res Commun 346(3):778–785PubMedCrossRef Hu Xiaoqu, Su Fengxi, Qin Li, Jia Weijuan et al (2006) Stable RNA interference of ErbB–2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo [J]. Biochem Biophys Res Commun 346(3):778–785PubMedCrossRef
Metadata
Title
Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene
Authors
Jia-jia Ma
Bi-liang Chen
Xiao-yan Xin
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 2/2009
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-008-0690-8

Other articles of this Issue 2/2009

Archives of Gynecology and Obstetrics 2/2009 Go to the issue